H.C. Wainwright raised the firm’s price target on Sensei Biotherapeutics (SNSE) to $30 from $5 and keeps a Buy rating on the shares following the recent reverse stock split and Q2 report.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNSE:
- Sensei Biotherapeutics reports Q2 EPS ($3.91) vs ($5.69) last year
- Sensei Biotherapeutics Regains Nasdaq Compliance
- Sensei price target raised to $35 at Stephens to reflect 1-for-20 reverse split
- Sensei Biotherapeutics Inc trading halted, news pending
- Upcoming Stock Splits This Week (June 16 to June 20) – Stay Invested